Perspectives in HPV Secondary Screening and Personalized Therapy Basing on Our Understanding of HPV-Related Carcinogenesis Pathways

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td class="align_left">CIN</td><td class="align_center">Regression</td><td class="align_center">Persistence of lesion</td><td class="align_center">Progression</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td class="align_left">LSIL (CIN1)</td><td class="align_center">60%</td><td class="align_center">30%</td><td class="align_center">10% (to HSIL)</td></tr><tr><td class="align_left">HSIL (CIN2, CIN3)</td><td class="align_center">30%</td><td class="align_center">60%</td><td class="align_center">10% (to invasive cancer)</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td><div>Abbreviations: CIN: cervical intraepithelial lesions; LSIL: low-grade squamous intraepithelial lesions; HSIL: high-grade squamous intraepithelial lesions.<br/></div></td></tr></table>

<div>Natural history of abnormal Pap smear evolution.</div>

Mediators of Inflammation

tab1

Table 1

Table 1: Perspectives in HPV Secondary Screening and Personalized Therapy Basing on Our Understanding of HPV-Related Carcinogenesis Pathways 